UP0 Stock Overview
A biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.80 |
| 52 Week High | US$54.50 |
| 52 Week Low | US$34.60 |
| Beta | 0.58 |
| 11 Month Change | -10.40% |
| 3 Month Change | -13.01% |
| 1 Year Change | 27.27% |
| 33 Year Change | -30.00% |
| 5 Year Change | 28.00% |
| Change since IPO | 2.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| UP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.7% | 0.8% | 0.8% |
| 1Y | 27.3% | -18.3% | 8.6% |
Return vs Industry: UP0 exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: UP0 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| UP0 volatility | |
|---|---|
| UP0 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: UP0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: UP0's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
| UP0 fundamental statistics | |
|---|---|
| Market cap | €4.15b |
| Earnings (TTM) | -€533.55m |
| Revenue (TTM) | €498.96m |
8.4x
P/S Ratio-7.8x
P/E RatioIs UP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UP0 income statement (TTM) | |
|---|---|
| Revenue | US$522.75m |
| Cost of Revenue | US$720.33m |
| Gross Profit | -US$197.59m |
| Other Expenses | US$361.40m |
| Earnings | -US$558.99m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.06 |
| Gross Margin | -37.80% |
| Net Profit Margin | -106.93% |
| Debt/Equity Ratio | 248.3% |
How did UP0 perform over the long term?
See historical performance and comparison